Japanese journal of clinical oncology · 2026
Association of radiotherapy with survival across metastatic patterns in metastatic small cell lung cancer in the immunotherapy era: a SEER analysis.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhao Shulin, Bo Zhixiang, Chen Ping, Gao Chu, Huang Jin, Shen Cheng
Аннотация
BACKGROUND: Radiotherapy (RT) combined with chemoimmunotherapy may have synergistic effects and improve treatment efficacy and survival in extensive-stage small cell lung cancer (ES-SCLC). However, its association with survival appears to be inconsistent across different metastatic patterns.
METHODS: Patients with metastatic SCLC diagnosed between 2020 and 2023 were identified from the Surveillance, Epidemiology, and End Results database. Propensity score matching (PSM), Kaplan-Meier analysis, and Cox regression were used to evaluate the association between RT and cancer-specific survival (CSS). Inverse probability of treatment weighting (IPTW) and overlap weighting were performed as sensitivity analyses.
RESULTS: A total of 4707 patients were included. Liver metastasis was the most common site-specific metastasis (44.1%), followed by bone (42.1%), brain (30.1%), and lung metastasis (16.1%). Multi-organ metastases without brain involvement were the most common metastatic pattern (21.2%), followed by other/unspecified (16.0%) and multi-organ metastases with brain involvement (15.5%). After 1:1 PSM, additional RT was associated with higher CSS in the liver only (HR, 0.68; 95% CI, 0.51-0.91; P = .009), lung only (HR, 0.55; 95% CI, 0.38-0.80; P = .002), multi-organ without brain (HR, 0.77; 95% CI, 0.64-0.92; P = .005), and other/unspecified cohorts (HR, 0.67; 95% CI, 0.54-0.82; P < .001). No significant association was observed in the bone only, brain only, or multi-organ with brain cohorts. IPTW and overlap weighting analyses yielded consistent results.
CONCLUSIONS: In the immunotherapy era, among patients with metastatic SCLC receiving first-line chemoimmunotherapy, the association between additional RT and CSS may vary across metastatic patterns.
METHODS: Patients with metastatic SCLC diagnosed between 2020 and 2023 were identified from the Surveillance, Epidemiology, and End Results database. Propensity score matching (PSM), Kaplan-Meier analysis, and Cox regression were used to evaluate the association between RT and cancer-specific survival (CSS). Inverse probability of treatment weighting (IPTW) and overlap weighting were performed as sensitivity analyses.
RESULTS: A total of 4707 patients were included. Liver metastasis was the most common site-specific metastasis (44.1%), followed by bone (42.1%), brain (30.1%), and lung metastasis (16.1%). Multi-organ metastases without brain involvement were the most common metastatic pattern (21.2%), followed by other/unspecified (16.0%) and multi-organ metastases with brain involvement (15.5%). After 1:1 PSM, additional RT was associated with higher CSS in the liver only (HR, 0.68; 95% CI, 0.51-0.91; P = .009), lung only (HR, 0.55; 95% CI, 0.38-0.80; P = .002), multi-organ without brain (HR, 0.77; 95% CI, 0.64-0.92; P = .005), and other/unspecified cohorts (HR, 0.67; 95% CI, 0.54-0.82; P < .001). No significant association was observed in the bone only, brain only, or multi-organ with brain cohorts. IPTW and overlap weighting analyses yielded consistent results.
CONCLUSIONS: In the immunotherapy era, among patients with metastatic SCLC receiving first-line chemoimmunotherapy, the association between additional RT and CSS may vary across metastatic patterns.